EGFR Inhibitors for Neoadjuvant and Adjuvant Therapy of NSCLC
Open Access
- 17 December 2015
- journal article
- Published by Peertechz Publications Private Limited in Journal of Surgery and Surgical Research
- Vol. 1 (3), 079-080
- https://doi.org/10.17352/2455-2968.000019
Abstract
No abstract availableThis publication has 15 references indexed in Scilit:
- Inferring alterations in cell‐to‐cell communication in HER2+ breast cancer using secretome profiling of three cell modelsBiotechnology & Bioengineering, 2014
- Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpointThe Lancet Oncology, 2014
- Gefitinib Versus Placebo in Completely Resected Non–Small-Cell Lung Cancer: Results of the NCIC CTG BR19 StudyJournal of Clinical Oncology, 2013
- The Role of Epidermal Growth Factor Receptor in Cancer Metastasis and MicroenvironmentBioMed Research International, 2013
- EGFR-Targeted Therapy for Non-Small Cell Lung Cancer: Focus on EGFR Oncogenic MutationInternational Journal of Medical Sciences, 2013
- Distinct Clinical Course of EGFR -Mutant Resected Lung Cancers: Results of Testing of 1118 Surgical Specimens and Effects of Adjuvant Gefitinib and ErlotinibJournal of Thoracic Oncology, 2012
- Tumor Response and Toxicity of Neoadjuvant Erlotinib in Patients With Early-Stage Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2012
- Phase II Study of Preoperative Gefitinib in Clinical Stage I Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2009
- Cancer Care Ontario and American Society of Clinical Oncology Adjuvant Chemotherapy and Adjuvant Radiation Therapy for Stages I-IIIA Resectable Non–Small-Cell Lung Cancer GuidelineJournal of Clinical Oncology, 2007
- Prognostic and Predictive Importance of p53 and RAS for Adjuvant Chemotherapy in Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2007